Skip to main content
Equibles
GILD logo

GILD · Gilead Sciences, Inc.

Track GILD — free

Use GILD with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about GILD

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$146.12 +2.68 (+1.87%) At close · Aug 21
Market Cap
$182.52B
Shares
1.24B

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$146.12 Open$144.52 Day$143.50–147.91 52W close$110.56–155.80 Avg vol 30d6.4M Short int24.4M · 2.0% float · 3.9d Short vol33% Last earningsAug 4, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Oct 31, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
      Market backdrop VIX 15.1 · calm Equity put/call 0.51
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +10%
      above
      Price vs 50-day avg +11%
      above
      RSI (14) 67
      neutral
      MACD trend Positive
      52-week position 79%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Neutral
      1-month return +13%
      trailing
      6-month return −3%
      trailing
      YTD return +19%
      this year
      Relative strength −14%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $132 › 200d $133 — 200d above 50d
      Institutional flow Distributing
      -2% holders QoQ · +152 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      1.97% of float · ▼ -3.5% MoM · 3.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      2,273 holders — near 3-yr high, broad support
      Squeeze score 50
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +10%
      Y/Y
      EPS growth +1684%
      Y/Y
      Free cash flow $9.5B
      Buyback $6.0B
      authorized
      Balance sheet $19.5B
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 27%
      annualized · 1-yr
      Max drawdown −22%
      past year
      ATR 2.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 3 of last 5
      Latest guidance · from the 8-K filed Aug 4, 2026
      Product sales · full year 2026 Initiated $30.1B – $30.4B
      Product sales excluding Veklury · full year 2026 Initiated $29.8B – $30.1B
      Veklury · full year 2026 Initiated $300M
      Diluted loss per share · full year 2026 Initiated $-3.75 – $-3.40
      prior FY $6.78 midpoint −152.7% Y/Y
      Non-GAAP projected product gross margin · full year 2026 Initiated 87%
      Prior guidance period ended · from the 8-K filed Oct 30, 2025
      Product sales · full-year 2025 $28.4B – $28.7B
      Veklury · full-year 2025 $1B
      Diluted EPS · full-year 2025 $6.65 – $6.85
      Product sales excluding Veklury · full-year 2025 $27.4B – $27.7B
      Guided vs delivered · last 5 settled
      Diluted EPS full-year 2025
      guided $6.65 – $6.85
      $6.78 In line
      Total product sales full year 2024
      guided $27.1B – $27.5B
      $28.75B Beat +5.3%
      GAAP-diluted EPS full year 2024
      guided $5.15 – $5.55
      $0.38 Miss −92.9%
      Total product sales full year 2023
      guided $26.7B – $26.9B
      $27.12B Beat +1.2%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +10% Bullish
      Price vs 50-day avg
      +11% Bullish
      RSI (14)
      67 Neutral
      MACD trend
      Positive Bullish
      52-week position
      79% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $132 › 200d $133 — 200d above 50d
      Institutional flow Distributing
      -2% holders QoQ · +152 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      1.97% of float · ▼ -3.5% MoM · 3.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      2,273 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $111 Now $146 · 79% Range high $156
      vs 200-day avg +10% vs 50-day avg +11%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Common stock repurchases $355M Q2 2026 —
      Dividends paid $1B Q2 2026 —
      Free cash flow non-GAAP $5.86B Six Months Ended June 30, 2026 —
      Non-GAAP effective tax rate non-GAAP -32.4% Six Months Ended June 30, 2026 —
      Non-GAAP operating margin non-GAAP -27.5% Six Months Ended June 30, 2026 —
      Non-GAAP product gross margin non-GAAP 87.2% Six Months Ended June 30, 2026 —
      Non-GAAP R&D expenses non-GAAP $1.4B Q2 2026 —
      Non-GAAP SG&A expenses non-GAAP $1.5B Q2 2026 —
      Operating cash flow $3.6B Q2 2026 —
      Product gross margin 79.3% Q2 2026 —
      Veklury sales $23M Q2 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Drug Manufacturers - General — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      GILD
      Gilead Sciences, Inc.
      this stock
      		$182.52B +19.0% +10.0% — 2.0%
      LLY
      ELI LILLY & Co
      		 $1.19T +16.8% +44.7% 42.3 1.0%
      JNJ
      Johnson & Johnson
      		 $654.05B +30.6% +6.0% 31.5 1.1%
      ABBV
      AbbVie Inc.
      		 $468.22B +16.0% +8.6% 74.9 1.3%
      MRK
      Merck & Co., Inc.
      		 $376.37B +44.9% +1.3% 122.0 1.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      2,273
      % held
      90.8%
      Net QoQ
      +49.6M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      1,513
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      24.4M
      Days to cover
      3.9d
      Change
      -876.3K sh
      View
      Short Volume
      Short vol %
      33%
      As of
      Aug 21, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      199
      Value
      $26.4K
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      36.5%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Buy
      Member
      Jared Moskowitz
      Amount
      $1.0K–$15.0K
      Traded
      May 6, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $29.4B
      Net income (FY)
      $8.5B
      EPS diluted
      $6.78
      View
      Buybacks
      Authorized
      $6.0B
      View
      Filings
      SEC Filings
      Latest
      10-Q
      Filed
      Aug 6, 2026
      This year
      16
      View
      Proposed Sales
      Value
      $738.0K
      Shares
      5.0K
      Filed
      Aug 20, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 4, 2026
      View
      Investor Relations
      Latest news
      CORRECTING and REPLACING Gilead S…
      Published
      Aug 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      GILD +5.6% +13.0% -2.6% +12.2% +19.1%
      SPY -1.4% +3.6% +11.6% +2.5% +12.3%
      vs SPY +7.0% +9.4% -14.2% +9.7% +6.8%

      Capital returns

      Latest dividend
      $0.82 / share · ex Jun 15, 2026
      Declared · upcoming
      $0.82 / share · ex Sep 15, 2026
      Raised 3.8%
      Paid (TTM)
      $3.22 / share · 4 payouts
      Dividend yield (TTM, derived)
      2.20%
      Buyback program · as of Aug 7, 2025
      Authorized
      $6.00B
      Spent (derived)
      —
      Remaining
      —

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 882095 CUSIP 375558103 13F (30d) 1799 filings 1746 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)